Anzeige
Mehr »
Donnerstag, 30.04.2026 - Börsentäglich über 12.000 News
Öl bricht über $108 und Wedgemount dreht die Produktion genau jetzt wieder an
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3ET7S | ISIN: CA47817E1034 | Ticker-Symbol: JNJ0
Frankfurt
30.04.26 | 08:07
17,800 Euro
-0,56 % -0,100
Branche
Konsumgüter
Aktienmarkt
Sonstige
1-Jahres-Chart
JOHNSON & JOHNSON CDR Chart 1 Jahr
5-Tage-Chart
JOHNSON & JOHNSON CDR 5-Tage-Chart
RealtimeGeldBriefZeit
17,80018,60009:02

Aktuelle News zur JOHNSON & JOHNSON CDR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiAbbVie outlines Skyrizi defense against new J&J plaque psoriasis rival Icotyde4
DiJ&J Sees Continued MedTech Improvement in Q1, Eyes Better 20264
MoJohnson & Johnson: FDA Grants Priority Review For IMAAVY315NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced the FDA has granted Priority Review to the supplemental Biologics License Application for IMAAVY as treatment for people living with...
► Artikel lesen
MoFDA gewährt J&J-Therapie gegen Anämie beschleunigtes Prüfverfahren5
MoFDA grants priority review for J&J's warm anemia treatment4
JOHNSON & JOHNSON CDR Aktie jetzt für 0€ handeln
MoFDA grants priority review to J&J's IMAAVY for rare blood disorder4
MoJohnson & Johnson: FDA grants Priority Review for IMAAVY (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)1.911Priority Review is granted to medicines that may offer significant improvements in safety or effectiveness for serious conditions like warm autoimmune hemolytic...
► Artikel lesen
FrJ&J's Xarelto, Invokana to become available through TrumpRx6
FrJohnson & Johnson (JNJ): Growth Engine at a Value Price9
FrJohnson & Johnson to acquire AtraVerse Medical and its transseptal access system1
FrJohnson & Johnson launches head-to-head PFA trial pitting Varipulse against Boston Scientific's Farapulse10
FrJohnson & Johnson to acquire medical device firm Atraverse Medical7
FrJ&J to buy private MedTech Atraverse to boost cardiac ablation portfolio3
FrJ&J's Icotyde approved by US FDA for plaque psoriasis3
23.04.JNJ set to snap six straight sessions of losses8
22.04.J&J's Imaavy demonstrates long-term disease control in myasthenia gravis5
22.04.Johnson & Johnson: New Data Reinforces Efficacy, Sustained Disease Control Of IMAAVY468NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced new data from the Phase 3 Vivacity-MG3 study and ongoing open label extension in a broad population of antibody-positive adults with...
► Artikel lesen
22.04.Johnson & Johnson wins CE mark for new Ethicon 4000 surgical stapler3
22.04.J&J's Imaavy shows sustained disease control in myasthenia gravis4
22.04.Johnson & Johnson: IMAAVY (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)746Through 120 weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+...
► Artikel lesen
Weiter >>
698 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1